^
    Back
    Association details:
    Biomarker:ROS1 G2032K
    Cancer:Non Small Cell Lung Cancer
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Lung Cancer
    Title:

    A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab

    Published date:
    03/26/2020
    Excerpt:
    ROS1 G2032 K is a novel mutation that mediates resistance to lorlatinib.
    DOI:
    10.1016/j.lungcan.2020.03.019